DALLAS, Sept. 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that renowned business columnist Gene Marcial of BusinessWeek, highlighted Access Pharmaceuticals in the most recent edition dated September 17, 2007. The article is also available on http://www.BusinessWeek.com under the 'Inside Wall Street' column.
The article focused upon the major opportunity Access' lead compound, ProLindac, has to offer shareholders. ProLindac, a platinum-based drug that is currently in Phase II clinical trials for ovarian and colorectal cancer, has the potential to be a next generation cancer therapy, which is currently dominated by Eloxatin, a current platinum drug that produces revenues in excess of $2 billion and is close to patent expiration in the U.S. Marcial also noted that Dr. Esteban Cvitkovic, Access' Vice-Chairman (Europe) and Senior Director, Oncology Clinical R&D, was responsible for developing Eloxatin during his tenure at Sanofi-Aventis. The article references certain products of Somanta Pharmaceuticals in the cancer area. While Access has executed a definitive merger agreement with Somanta, the acquisition has not yet closed and the closing is still subject to the satisfaction of the closing conditions set forth in the merger Agreement. The consummation of the acquisition is subject to numerous closing conditions.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company
that develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include ProLindac(TM),
currently in Phase II clinical testing of patients with ovarian cancer and
MuGard(TM) for the management of patients with mucositis. The company also
has other advanced drug delivery technologies including
Cobalamin(TM)-mediated targeted delivery and oral drug delivery. Access has
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved